AzTrials
AzTrials

Trauma-induced CoagulopathyNCT00744003

An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients

An observational study of Trauma-induced Coagulopathy, run by Emory University at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Trauma continues to be the major killer of young Americans, mainly due to hemorrhage or brain injury. In trauma centers, up to a quarter of these severely injured patients arrive with a coagulopathy and thereby experience an increased risk of death, despite the current standard of medical and surgical management. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Trauma-induced Coagulopathy
How many people
0 participants
Where
1 siteUnited States
Study dates
Jul 2008to Jul 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Trauma patients arriving at a Level I trauma center who activated the Trauma Team criteria for a "stat pack" trauma admission

Who may be able to join

  • > 17 years of age
  • GMH Emergency Care Center (ECC) admission with trauma team activation - referred to by GMH nomenclature as a "STAT-pack." Trauma team activation criteria were developed from standard criteria published by the American College of Surgeons Committee on Trauma and published in Resources for Optimal Care of the Injured Patient manual 2006 edition and modified for GMH use. A trauma patient is declared a STAT-pack if they meet one of the following criteria:
  • Ejection from a motor vehicle or motorcycle
  • Extremes of age: pediatric < 6 years of age or an adult > 65 yrs of age
  • One of the following: HR > 120; RR > 30; Systolic BP < 100; GCS < 13; Basal temperature < 35 degrees C
  • Penetrating trauma to head/neck/thorax/abdomen including flank and back/antecubital fossa/groins/popliteal space
Show all 12Show fewer
  • Suspected neurological injury i.e. spinal cord injury
  • Traumatic amputation above the wrist or ankle
  • Mangled or crush to an extremity
  • History of trauma in a patient who is combative, has deteriorating vital signs or is hemorrhaging from an open wound
  • Physician or EMS discretion
  • Patients admitted to GMH ECC directly from the site of injury

Who cannot join

  • < 18 years of age
  • Any patient who is pronounced dead by health care personnel prior to any blood sampling
  • Any patient who arrives undergoing CPR and is pronounced dead without resumption of vital signs
  • Transfers from other health care facilities
  • Any patient known to be taking anti-coagulant or anti-platelet medicine
  • Any patient with a known predisposing history of a coagulation or platelet defect

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Grady Memorial Hospital

    Atlanta, Georgia, 30303

Other trials in United States

About this study

Official title: Early Trauma Induced Coagulopathy (ETIC): A Pilot Study to Determine Its Definition and Risk Factors

Trauma continues to be the major killer of young Americans, mainly due to hemorrhage or brain injury. In trauma centers, up to a quarter of these severely injured patients arrive with a coagulopathy and thereby experience an increased risk of death, despite the current standard of medical and surgical management. The PI for this grant proposal is a fellowship-trained trauma surgeon who works full-time at Grady Memorial Hospital (GMH), the only Level I Trauma Center in Atlanta. It is only one of four Level 1 trauma centers for the entire state of Georgia. This research is a direct extension of the retrospective research the PI has previously published. Her retrospective research discovered a previously undescribed form of coagulopathy, early trauma induced coagulopathy (ETIC), which cannot be explained by present paradigms. Two civilian trauma articles as well as military data from the Iraq war have substantiated the occurrence of ETIC, but no prospective literature has defined it or its kinetics. More importantly, the results from these studies represent a new paradigm shift, in which ETIC appears to be a primary dysfunction which is independently associated with death. Therefore, its early identification and correction is crucial for our mechanistic understanding, and ultimately, our choice of interventions and improved survival. GMH is a high-volume trauma center that sees patients with a variety of injury mechanisms, and, therefore, is the perfect setting to confirm ETIC. First, the project will confirm the prevalence of ETIC with an observational prospective cohort of injured patients. Data on the coagulation system and risk factors, both known and suspected, of all patients will be collected upon patient arrival as well as patient outcome with all identifying information protected. This is the first prospective research project that will allow simultaneous control of confounders associated with outcome and thereby scientifically validate the occurrence of ETIC. One unique component of our data collection is a focus on the timing of events as they relate to the development and consequences of coagulopathy, to account for the dynamic process. At the completion of data collection, a matched cohort of ETIC and non-ETIC blood samples will be tested for coagulation factors to provide insight into ETIC's pathophysiology. In the short term, our conclusions will assist us in our approach to resuscitation of the bleeding trauma patient as some trauma centers have already started to change protocols based on our present incomplete understanding of trauma-induced coagulopathy. In addition, the coagulation system data collected in this study will lead to pathophysiological answers and to more refined hypotheses for future research at a coagulation system level. Ultimately an understanding of ETIC will lead to a more effective, tailored treatment. Our main study hypothesis is that post-trauma coagulopathy is a primary dysfunction that occurs early after a traumatic event in up to 25% of all trauma patients triaged to Trauma Center care.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of coagulopathy as defined by abnormal PT/INR

    Measured: Admission to Trauma Center

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Aug 2008 (estimated)
  2. Study startJul 2008
  3. Primary completionJun 2009
  4. Study completionJul 2009

Why it stopped: PI no longer at Emory; no participants enrolled, study not conducted

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00744003
Sponsor's protocol ID
IRB00006685
Other IDs
ETIC Study
Status last verified
Nov 2013
First submitted
27 Aug 2008
Last updated
18 Nov 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Trauma-induced Coagulopathy, run by Emory University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 18 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development of coagulopathy as defined by abnormal PT/INR (time frame: Admission to Trauma Center). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in